Clinical trials: Non-Hodgkin
Peripheral T-cell Lymphoma
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for belinostat when combined with CHOP regimen and establish the recommended belinostat dose for the Phase 3 study.
- Trial name
- NCT01839097
- Testing
- Belinostat, CHOP
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Acrotech Biopharma Inc.
B Cell Lymphoma
A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
This is a multicenter, randomized, double-blind, parallel group study to compare the PK, safety, tolerability, immunogenicity and PD of JHL1101 vs Rituxan in subjects with CD20-positive B cell lymphoma.
- Trial name
- NCT03670888
- Testing
- JHL1101, Rituximab
- Where
- 2 sites in China
- Volunteers
- 1 people
- Sponsor
- JHL Biotech, Inc.
Diffuse Large B-Cell Lymphoma
An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma
This multicenter, observational study will evaluate the correlation between clinical and biological factors and International Prognostic Index (IPI) as prognostic factors in patients with diffuse large B-cell lymphoma receiving…
- Trial name
- NCT01724294
- Where
- Romania
- Volunteers
- 113 people
- Sponsor
- Hoffmann-La Roche
CTCL/ Mycosis Fungoides, CTCL
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
- Conditions
- CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
- Trial name
- FLASH2 (NCT06470451)
- Testing
- Hypericin
- Where
- 17 sites in United States
- Volunteers
- 70 people
- Sponsor
- Soligenix
Lymphoma, Non-Hodgkin
A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non-Hodgkin's Lymphoma (R/R NHL).
- Trial name
- NCT04860466
- Testing
- CC-96673
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 9 people
- Sponsor
- Celgene
Non Hodgkin Lymphoma
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin…
- Trial name
- NCT06088654
- Testing
- IPH6501
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 23 people
- Sponsor
- Innate Pharma
Prolapsed Lumbar Disc, Prolapsed Cervical Disc
Patient Registry to Observe Outcomes Following Implantation of the VariLift Interbody Fusion Device
The registry has been designed as a prospective, observational program for patients undergoing lumbar or cervical fusion using VariLift device with the ultimate goal to aid in the development of strategic treatment pathways and…
- Conditions
- Prolapsed Lumbar Disc, Prolapsed Cervical Disc, Intervertebral Disc Degeneration, Spondylolisthesis, Grade 1
- Trial name
- NCT01944345
- Where
- 3 sites in United States
- Volunteers
- 69 people
- Sponsor
- Wenzel Spine
Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide.
- Trial name
- OLYMPIA-5 (NCT06149286)
- Testing
- Odronextamab, Lenalidomide, Rituximab
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 580 people
- Sponsor
- Regeneron Pharmaceuticals
Dementia Moderate, Dementia, Mild
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
- Conditions
- Dementia Moderate, Dementia, Mild, Alzheimer Disease
- Trial name
- XanaMIA (NCT06125951)
- Testing
- Xanamem
- Where
- 34 sites in United States, Australia
- Volunteers
- 247 people
- Sponsor
- Actinogen Medical
CTCL
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell…
- Trial name
- NCT06854653
- Testing
- PTX-100
- Where
- 15 sites in United States, Australia and 2 more
- Volunteers
- 115 people
- Sponsor
- Prescient Therapeutics, Ltd.
Peripheral T Cell Lymphoma, Progression, Disease
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
This study is to evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria…
- Trial name
- NCT03150602
- Testing
- Pralatrexate
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- Taiwan Mundipharma Pharmaceuticals Ltd.
Mantle Cell Lymphoma
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
The purpose of this study is to test the safety of Iodine-131 Anti-B1 Antibody followed by CHOP and to see what effects it has on patients with previously untreated mantel cell lymphoma.
- Trial name
- NCT00022945
- Testing
- Iodine-131 Anti-B1 Antibody, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
- Where
- 3 sites in United States
- Sponsor
- Corixa Corporation
T-Cell Lymphoma, B-Cell Lymphoma
A Study for Patients With Non-Hodgkin's Lymphomas
In this study, all patients will get investigational drug. There will be no comparator drug. This study will evaluate three tumor types: T-cell lymphoma, Indolent B-cell lymphoma, and Aggressive B-cell lymphoma.
- Trial name
- NCT00542919
- Testing
- enzastaurin
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 57 people
- Sponsor
- Eli Lilly and Company
Lymphoma, Non Hodgkin
An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
This is a prospective, observational, longitudinal, multicenter study of patients with newly diagnosed follicular Non Hodgkin's Lymphoma (NHL) designed to delineate differences in clinical outcome by comparing the effectiveness…
- Trial name
- NCT00097565
- Volunteers
- 2,740 people
- Sponsor
- Genentech, Inc.
Non-Hodgkin's Lymphoma
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
This is a multicenter, open, Phase I clinical study to evaluate the safety and tolerability of F01 in subjects with relapsed/refractory non-Hodgkin lymphoma, and to determine MTD and/or RD.
- Trial name
- NCT06206902
- Testing
- After preconditioning with chemotherapy, F01 will be evaluated.
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
Lymphoma, T-Cell, Peripheral
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
A Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell…
- Trial name
- NCT06947967
- Testing
- CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone), Tucidinostat
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Moderate or Severe Submental Fullness
Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area
To determine the dosing interval, optimal dose, evaluate safety, and efficacy of AYP-101 S.C injection for the reduction of Submental Fat (SMF).
- Trial name
- NCT05266729
- Testing
- Polyene Phosphatidylcholine
- Where
- South Korea
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AMIpharm Co., Ltd.
Lymphoma, Diffuse Large B-Cell
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, nonrandomized, open label, phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on…
- Trial name
- NCT02226965
- Testing
- PNT2258
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced or…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049699
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Asthma (Diagnosis)
Longitudinal Phenotyping and Endotyping Study in Adult Patients With Mild, Moderate, or Severe Asthma
Background and study aims: The purpose of this research registry is to understand how asthma varies from person to person and monitor changes that may occur over time.
- Trial name
- MAPLE-UK (NCT07189806)
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Hvivo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.